GLP-1 drug lixisenatide blocks alpha-synuclein spread in Parkinson's disease through LAG3 receptor mechanism | Research

The takeaway

Lixisenatide reduced α-synuclein phosphorylation, aggregation, and neuron-to-neuron propagation in PD models by inhibiting LAG3-mediated seeding, while alleviating motor dysfunction and dopaminergic neurodegeneration at 20 weeks in mice.

Blocks α-synuclein spread via LAG3
Lixisenatide inhibited neuron-to-neuron propagation of toxic α-synuclein through LAG3 receptor—revealing a specific disease-modifying mechanism for GLP-1 drugs in Parkinson's

What the researchers found

Lixisenatide: ↓α-synuclein phosphorylation, aggregation, propagation. ↓Mitochondrial dysfunction and apoptosis in cells. 20-week mouse treatment: improved motor function, protected dopaminergic neurons. Mechanism: inhibited LAG3-mediated neuron-to-neuron α-synuclein seeding.

Why it matters

This identifies the specific mechanism—LAG3-mediated seeding inhibition—by which GLP-1 drugs could slow PD progression. This goes beyond symptom management to disease modification.

How the study worked

In vitro: α-synuclein PFF-treated cells. In vivo: stereotactic PFF injection into mouse striatum + 20-week lixisenatide treatment. α-Synuclein pathology, motor assessment, dopaminergic neuron counts, LAG3 expression.

What this study cannot tell us

Mouse model with PFF injection. Lixisenatide (short-acting) may differ from long-acting GLP-1 drugs. 20 weeks may not capture long-term PD progression. LAG3 mechanism needs human validation.

How to read the evidence

Rigorous preclinical study with both in vitro mechanism and 20-week in vivo disease modification. Strong mechanistic evidence.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may be the first disease-modifying therapy for PD if they can truly block α-synuclein spread. The LAG3 mechanism provides a specific target to optimize and monitor.

Questions still open

Do long-acting GLP-1 drugs (semaglutide) also inhibit LAG3-mediated seeding?
Could combining GLP-1 drugs with anti-LAG3 antibodies enhance PD treatment?
Is LAG3 expression a biomarker for GLP-1 drug response in PD?

Common questions

How could GLP-1 drugs treat Parkinson's disease?

This study shows lixisenatide blocks the spread of toxic α-synuclein protein between brain cells—the process that drives Parkinson's progression. It does this by inhibiting a specific receptor (LAG3) that neurons use to take up the toxic protein. This could slow or halt disease progression rather than just managing symptoms.

Is this different from current Parkinson's treatments?

Yes, fundamentally. Current PD drugs only manage symptoms (primarily by replacing dopamine). This GLP-1 drug approach targets the underlying disease process—the spread of toxic protein aggregates. If confirmed in humans, it would be the first treatment to actually slow Parkinson's disease progression.

Read the original research

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease.

Neural regeneration research

View on PubMed ↗Publisher’s paper ↗

Citation

Sun, Shangqi; Huang, Liqin; Jiang, Gege; Xie, Guanfeng; Li, Xiaoyi; Wang, Xiufeng; Guo, Hongxiu; Wang, Cailin; Zheng, Siyi; Li, Gang; Xiong, Jing. (2025). Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease.. Neural regeneration research. https://doi.org/10.4103/NRR.NRR-D-24-00941